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ABSTRACT  
Caffeic acid phenethyl ester (CAPE) is a polyphenolic active compound present in popular 
apiproduct, ‘propolis’ obtained from beehives. Though it has broad therapeutic capability, the 
bioavailability of CAPE is limited due to poor solubility.  In this study, we report novel 
cocrystals of CAPE engineered using coformers such as caffeine (CAF), isonicotinamide (INIC), 
nicotinamide (NIC) with enhanced solubility and bioavailability of CAPE. The cocrystals were 
prepared by microwave-assisted cocrystallization and characterized using PXRD, DSC and 
Raman spectroscopy. PXRD and DSC confirm the successful formation and phase purity of 
CAPE-CAF, CAPE-INIC and CAPE-NIC cocrystals. Raman spectra of CAPE cocrystals 
complement these results in confirming the formation of novel crystalline phases. CAPE-NIC 
cocrystal was further subjected to X-ray crystallography to understand its molecular arrangement 
and hydrogen bonding in the crystal structure. The CAPE-NIC cocrystal structure is found to be 
stabilized by a rare 1,2-benzenediol-amide heterosynthon. Cocrystallization of CAPE with NIC 
improved its aqueous solubility and pharmacokinetic profile thereby demonstrating 2.76 folds 
escalation in bioavailability. 
1. Introduction 
Polyphenolic compounds either synthetic or obtained from natural sources play an important role 
in therapeutic and nutritional applications.
1,2,3
 They are known to exhibit diverse 
pharmacological effects such as antioxidant, antimicrobial, anti-inflammatory, anticancer, 
antiviral, immunomodulatory, etc.
4,5,6,7
  Despite broad therapeutic utility, the poor aqueous 
solubility of polyphenols limits their bioavailability and makes their clinical efficacy 
questionable.
1,2,8
 Therefore, improving the physicochemical properties of polyphenols forms a 
 3 
major focus of research worldwide. Pharmaceutical cocrystallization is a process by which a 
drug molecule and a coformer are brought together into the same crystal lattice to prepare novel 
solid forms of APIs with tailored physicochemical properties. This method has been successfully 
adapted to modulate the solubility of various polyphenolics. For example, the solubility and 
dissolution rate of curcumin and myricetin were improved by cocrystallizing with suitable 
coformers.
9, 10
 Further, cocrystallization was found to be advantageous in altering the 
pharmacokinetic profile of polyphenolics such as quercetin and epigallocatechin-3-gallate.
11, 12
 
Binary solid composites, e.g. amorphous solid dispersions and eutectics are complementary 
strategies to improve the solubility of polyphenolics.
13, 14, 15
 
Caffeic acid phenethyl ester (CAPE) is a polyphenolic active present in popular 
apiproductpropolis, obtained from bee hives. CAPE is known to possess a wide array of 
pharmacological activities such as antioxidant, anti-inflammatory, antitumor, antibacterial, 
antiviral, neuroprotective, hepatoprotective, cardioprotective and immunostimulant.
16-23 
Although numerous preclinical studies demonstrate the effectiveness of CAPE, its therapeutic 
utility is limited on account of its poor bioavailability which is ascribed to its poor aqueous 
solubility.
24, 25
 Most of the documented scientific reports focus on chemical synthesis 
26, 27, 28
and 
biological evaluation of CAPE or its derivatives.
29,16
 However, a systematic analysis of its crystal 
structures directed towards improving its physicochemical properties is not known in the 
literature. A benzene solvate of CAPE is reported,
30
but its structural details were not found in the 
Cambridge Structural Database (CSD). Thus, till date there are no X-ray crystal structures on 
crystal forms of CAPE, either as single or multicomponent forms. The current study explores 
novel cocrystals of CAPE directed towards modulating its physicochemical properties. The 
microwave assisted cocrystallization
31
technique was used to screen CAPE with various GRAS 
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(Generally Regarded As Safe) listed coformers.  In this study, we have found three novel 
cocrystals of CAPE with caffeine (CAF), isonicotinamide (INIC) and nicotinamide (NIC).  The 
generation of novel crystalline forms of CAPE and understanding their structure-property 
relationships with special emphasis on improving its poor solubility and bioavailability forms the 
major focus of this article. 
 
Scheme 1.Chemical structures of CAPE  and coformers. 
 
2. Experimental  
2.1 Materials and Methods 
CAPE, 97% pure, CAF, NIC, INIC, gallic acid, p-coumaric acid, curcumin, isoniazide, 
theophylline, urea, ibuprofen (purity >98%) and taxifolin analytical standard were purchased 
from Sigma-Aldrich Company Ltd., UK. Ethanol(>99% pure) and acetonitrile (>99% pure) were 
also procured from Sigma-Aldrich Company Ltd., UK.  
 
 5 
2.2. Synthesis of CAPE Cocrystals 
A common procedure was used to screen all coformers listed above (SI1,ESI†) using microwave 
assisted cocrystallization technique for generation of cocrystals with CAPE. Equimolar amount 
of CAPE and the coformer were mixed with ethanol to obtain 40 % w/w slurry in a 30 mL glass 
tube. The slurry was subjected to microwave irradiation in microwave reactor (Monowave 300, 
Anton Paar, Gmbh, Austria) to induce cocrystallization. The operating conditions were target 
temperature (80 °C), hold time (60 sec) followed by cooling to 40 °C, the solid product was dried 
and subjected to further characterization.  
2.3. Powder X-ray diffraction (PXRD) 
The microwave processed materials were screened for cocrystal formation on Bruker D8 
advanced diffractometer (X-ray wavelength λ = 0.154 nm, source Cu-Kα, voltage 40kV) with 
filament emission of 40 mA current. The samples were scanned from 2 to 30° 2θ at a scan speed 
of 0.01° step width.  
2.4. Differential scanning Calorimetry (DSC) 
The microwave processed materials were subjected to thermal analysis using TA Instruments 
DSC 2000 differential scanning calorimeter. The samples were subjected to heating from 20°C 
to their respective melting temperature at rate of 10°C/ min in DSC cell under inert nitrogen 
environment. Standard aluminum pans were used. 
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2.5. Raman spectroscopy 
Raman spectra were recorded using Renishaw In via Reflex bench top spectrometer coupled with 
683 nm stabilized diode (Renishaw Plc., UK). A laser spot of diameter (footprint) 2 μm was 
obtained at specimen using a 100X objective lens. The spectra were collected using extended 
scanning mode over the wave number region of 3500–100 cm-1. 10 scans were collected for each 
sample. Data analysis was performed using Galactic Grams AI 8.0 spectroscopy software 
(Thermo Electron Corporation). 
2.6. X-Ray Crystallography 
Single crystal X-ray data on CAPE-NIC cocrystal was collected on the Xcalibur Gemini EOS 
CCD diffractometer (Oxford Diffraction, Yarnton, UK) using Mo-Kα, radiation at 298 K. Data 
reduction were performed using CrysAlisPro (version 1.171.33.55). OLEX2-1.0 and SHELX-TL 
97 were used to solve and refine the reflections data. Non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms on O and N were experimentally located in difference electron 
density maps. All C–H atoms were fixed geometrically using HFIX command in SHELX-TL. A 
check of the final CIF file using PLATON did not show any missed symmetry. X-Seed was used 
to prepare packing diagrams. The X-ray data are deposited with the Cambridge Crystallographic  
Data Centre (www.ccdc.cam.ac.uk) (CCDC No. 1478155). 
2.7. Equilibrium Solubility measurements 
CAPE and the cocrystal samples were individually added in small portions to 1 mL distilled 
water at room temperature (25 ± 0.5 °C) and stirred at 600 rpm. The addition of solids was 
stopped once they showed precipitation in the solvent. The systems were stirred for further        
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24 hrs to ensure equilibration of the solids with the solvent. The samples were filtered using    
0.45 µm nylon filter. The filtrate was suitably diluted and subjected to High Performance Liquid 
Chromatographic (HPLC) analysis on Waters e-2695 system integrated with a PDA 2998 
detector, Empower 3 software and Waters symmetry C18 column (4.6 × 250 mm, 5 µm) 
maintained at 25 ± 0.5 °C throughout study, see SI2ESI†. Amount of CAPE solubilized was 
calculated from calibration curve by plotting the known concentration at each dilution vs. the 
corresponding peak area. 
2.8. In vivo pharmacokinetics 
Male Wistar rats (n = 3 per group) weighing 200–250 g were purchased from National 
Toxicology Centre, Pune, India. CAPE and CAPE-NIC cocrystal samples were administered per 
oral at a dose of 100 mg CAPE per kg body weight. Blood was collected from retro-orbital 
plexus of rats at different time points as: 0, 5, 10, 15, 30, 45, 60, 120, 240, and 360 min. and 
analyzed for CAPE plasma concentration, see SI3,ESI† for more details.  
3. Results and Discussion 
Data mining of the crystal structure database (CSD) in conjunction with the crystal engineering 
principles comprise the basic design elements for fabrication of multi-component cocrystals.
34-39
 
Considering the nature of functional groups in CAPE molecule, coformers with complementary 
functional moieties were selected so as to form stable cocrystals. The primary functional groups 
in CAPE are 1,2-benzenediol and ester moieties. In literature, COOH, CONH2 and pyridine 
functional groups have been reported to assemble with hydroxyl containing molecules.
33, 37
 
Accordingly, CAPE was cocrystallized with GRAS listed coformers containing these functional 
groups. A complete list of all the coformers are listed in Table SI1, ESI†.  
 8 
3.1. Powder X-ray Diffraction 
PXRD was employed as a fingerprint tool to examine the crystallinity and novelty of CAPE 
cocrystals. The experimental powder patterns of bulk materials of CAPE cocrystals and their 
respective individual components are shown in Figure 1a and Figure 1b. The new and unique 
diffraction peaks in the powder XRD patterns of cocrystal samples different from that of pure 
CAPE and coformers confirm cocrystallization.   
 
Figure 1a. Experimental powder diffraction patterns of A) pure CAPE; B) CAPE-CAF; C) 
CAPE-INIC and D) CAPE-NIC 
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Figure 1b.Calculatedpowder diffraction patterns of pure A) caffeine; B) INIC and C) NIC  
3.2. Differential Scanning Calorimetry 
Differential scanning calorimetric analysis displayed unique thermal behavior and the phase 
purity of CAPE cocrystals. Interestingly, none of the cocrystals exhibited a melting point in 
between that of the corresponding individual components as observed in certain cocrystal 
systems
35
 (Figure 2a and 2b). Instead, all the cocrystal phases exhibited lower melting point as 
compared to CAPE and the respective coformers. The cocrystal melting points showed a direct 
dependence on the coformer melting point, i.e. higher melting cocrystal was formed by a higher 
melting coformer (Table 1). Further, heat-cool-heat experiments on these cocrystals indicated 
that they did not undergo recrystallization on cooling, possibly the recrystallization event 
 10 
followed a different cooling profile than the method adapted during our DSC analysis. (SI4, 
ESI†) 
 
Figure 2a. DSC Heating curves for a) pure CAPE; b) CAPE-CAF; c) CAPE-INIC; d) CAPE-
NIC; e) CAF f) INIC and g) NIC 
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Figure 2b. DSC Heating curves for a) pure CAPE; b) CAF; c) INIC and d) NIC. 
Table 1. DSC melting points of CAPE cocrystals and their conformers. 
S. No. CAPE cocrystal Cocrystal melting 
Point (°C) 
Coformer Coformer melting 
Point (°C) 
1 CAPE-NIC 107.01 Nicotinamide 129.04 
2 CAPE-INIC 106.35 Isonicotinamide 158.23 
3 CAPE-CAF 113.64 Caffeine  236.73 
Melting point of CAPE is 129°C 
 
3.3. Raman spectroscopy 
CAPE and its cocrystals were characterized by Raman spectroscopy in order to ascertain the 
influence of solid state modification on the vibrational states of participating atoms and 
differentiate the novel crystalline phases from the starting materials. In the Raman spectrum of 
CAPE, the ester C=O stretch occurs at 1680.55 cm
-1
, the asymmetric and symmetric C=C stretch 
occurs at 1598.7 and 1451.8 cm
-1
 and the C-O stretch occurs at 1156.5 cm
-1
. Similarly in the 
Raman spectrum of NIC, the N-H stretch occurs at 3368.9 cm
-1
, the C=O at 1676.39 cm
-1
 and C-
O at 1159.3 cm
-1
. On forming cocrystal, the amide C=O of NIC undergoes a red shift to 1634.7 
cm
-1
 indicating the enhanced single bond character of the C=O group on forming a hydrogen 
bond with the phenolic O-H of CAPE. The other cocrystals where crystal structures are not 
available currently, changes in their vibrational patterns may be explained through Raman 
spectrum. In pure INIC, the N-H stretch occurs at 3357.8 cm
-1
 and the C=O at 1676.3 cm
-1
. In 
the cocrystal, the amide C=O undergoes a blue shift to 1697.1 cm
-1
 and C-O to 1163.4 cm
-1
. In 
pure CAF, the C=O appears at 1695 cm
-1
 which undergoes a red shift to 1687.5 cm
-1
 in the 
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cocrystal. Thus, the Raman spectroscopy complement with other characterization techniques in 
establishing the formation of novel crystalline phases. 
 
Figure 3. Raman spectrum of CAPE-NIC in comparison to its starting materials 
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Figure 4. Raman spectrum of CAPE-INIC in comparison to its starting materials 
 
Figure 5. Raman spectrum of CAPE-CAF in comparison to its starting materials 
3.4. Crystal Structure Analysis 
CAPE-NIC cocrystal 
Among the novel crystalline phases, crystal structure of CAPE-NIC was determined by SC X-ray 
crystallography. The structural parameters of CAPE-NIC are shown in Table 2 and the hydrogen 
bond parameters are listed in Table 3. 
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Table 2. Crystallographic Parameters of CAPE-NIC cocrystal. 
Emp. Form. C23H22N2O5 
Form. Wt. 406.43 
Cryst. Syst. Monoclinic 
Sp. Gr. P21/c 
T (K) 298(2) 
a (Å) 22.0039(15) 
b (Å ) 5.2382(4) 
c (Å ) 17.9644(16) 
α (º) 90 
β (º) 99.975(8) 
γ (º) 90 
Z 4 
V (Å3) 2039.3(3) 
Total No. of Reflns. 6455 
Unique Reflns. 3457 
Obsd. Reflns. 2391 
Parameters 287 
R1 0.0500 
wR2 0.1470 
GOF 1.021 
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Table 3.  Hydrogen bond distances and angles in CAPE-NIC cocrystal (neutron-normalized 
NH 1.030 Å, OH 0.938 Å, and CH 1.080 Å distances). 
 
This 1:1 stoichiometric cocrystal crystallized in monoclinic P21/c space group. A two-point 
heteromeric interaction between the 1,2-benzenediol moiety of CAPE and the amide of  NIC 
(O1–H1∙∙∙O5, 1.96Å, 148°; N2–H2B∙∙∙O2, 2.26Å, 137°) is the primary H-bonding synthon in this 
cocrystal (Figure 6). Further, these heterodimers are connected through N–H∙∙∙O (N2-H2B···O1 
(phenolic oxygen), 2.58 Å, 114°; N2-H2A···O5 (amide oxygen), 2.29Å, 150°) H-bonds, 
extending them into the 2-dimensional space. The phenolic –OH (O2H2) further propagates this 
molecular assembly into the third dimension through O-H···N (O2-H2···N3 (pyridyl N), 1.74Å, 
164°) H-bond with the adjacent pyridyl nitrogen. Apart from these strong hydrogen bonding 
synthons, weak C-H···O (C16-H16···O4, 2.67Å, 167°) and C-H···π interactions ably assist in 
stabilizing the 3D packing in this cocrystal (Figure 7). The benzenediol-amide heterosynthon 
between CAPE and NIC is relatively rare interaction as compared to their respective 
homosynthons and competing heterosynthons. A  CSD search for cocrystals with 1, 2-
benzenediol and primary amide functional group lends credence to this statement (Table SI5, 
DH∙∙∙A D∙∙∙A (Å) H∙∙∙A (Å) DH∙∙∙A (°) Symmetry code 
CAPE–NIC (1:1) 
O1H1∙∙∙O5 2.790 1.96 148 x+1,+y1/2, z+1/2+1 
N2H2B∙∙∙O1 3.068 2.58 114 x+1,+y1/2, z+1/2+1 
N2H2A∙∙∙O5 3.088 2.29 150 x, 1+y, z 
O2H2∙∙∙N3 2.708 1.74 164 x,+y-1,+z+1 
C16H16∙∙∙O4 3.545 2.67 157 x+2,+y1/2,z+1/2+1 
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ESI†). A CSD search (version 5.37, March 2016) with these functional groups on chemically 
different molecules resulted in 28 hits. Of these 24 crystal structures were stabilized by 
competing homosynthons (OH···OH and amide-amide) heterosynthons such as acid-amide, OH-
pyridine etc. Only four structures form the 1,2-benzenediol and amide heterosynthon. The 
predominance of crystal structures stabilized by competing heterosynthons indicates the diol-
amide heterosynthon as a much weaker interaction. In the CAPE-NIC structure, the diol-amide 
heterosynthon was favored due to the absence of other functional groups and preferred over the 
competing homosynthons. 
 
Figure 6. CAPE and NIC molecules connected through heteromeric two point synthon which are 
further held through N-H∙∙∙O H-bonds. The O-H∙∙∙N (pyridine) interaction is highlighted through 
a blue circle. 
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Figure 7. Weak C-H∙∙∙O and C-H∙∙∙π interactions further stabilize the CAPE-NIC crystal 
structure. 
 
3.5. Equilibrium Solubility 
The primary objective behind developing cocrystals of CAPE was to address its poor solubility, 
which significantly lowers its bioavailability limiting its efficacy. Our objective was based on the 
hypothesis that the high solubility coformers would alter the hydrogen bond patterns in the 
CAPE, which would improve its aqueous solubility envisaging enhancement in bioavailability. 
Equilibrium solubility experiments on CAPE and its cocrystals were performed in distilled water 
and the samples were analyzed by HPLC. The HPLC chromatograms demonstrated retention 
time (Rt) for standard solutions of CAPE, CAF, INIC and NIC to be 3.702 ± 0.02, 3.123 ± 0.03, 
2.945 ± 0.02 and 3.006 ± 0.01 min, respectively and the same were observed for respective 
cocrystals (Figure SI6, ESI†). Solubility experiments, apart from confirming the poor aqueous 
solubility of CAPE (0.021± 0.0013 mg/mL), highlighted the advantage in forming cocrystals 
where the CAPE-CAF, CAPE-INIC and CAPE-NIC exhibited about 5.5, 7.5 and 17.7 times 
higher solubility as compared to pure CAPE (Table 4). Interestingly, the solubility profiles of 
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CAPE cocrystals are inversely related to their melting point. The lower melting CAPE-NIC 
exhibited higher solubility followed by CAPE-INIC and CAPE-CAF. Significant improvement 
in the aqueous solubility of CAPE-NIC may be ascribed to the higher solubility documented for 
nicotinamide in water.
34,35 
. Further, the BFDH (Bravais, Friedel, Donnay and Harker) model 
hints (since this method is based purely on geometric considerations and completely neglects 
energetics, the result is mostly a qualitative view) at the morphology of CAPE-NIC cocrystal 
(Figure SI7, ESI†) where the hydrophilic -diol groups of CAPE project out of the major (100) 
face of the CAPE-NIC cocrystal structure burying the hydrophobic skeleton inside, enabling 
favorable interaction with the water molecules and thus increasing its solubility.
40
 
 
Table 4. Equilibrium solubility values of CAPE and its cocrystals. 
Compound Equilibrium Solubility 
(mg/mL) 
X fold increment 
compared to CAPE 
Melting point of 
cocrystal (°C) 
CAPE 0.021 ± 0.0013 - 129 
CAPE-CAF 0.115 ± 0.0011 5.5 113.48 
CAPE-INIC 0.158 ± 0.0054 7.5 107.98 
CAPE-NIC 0.371 ± 0.0052 17.7 106.67 
 
3.6. In vivo pharmacokinetics 
The poor water solubility of CAPE hampers its pharmacokinetic profile especially in terms of 
absorption upon oral administration. The present study was performed to trace the influence of 
cocrystallization of CAPE on its bioavailability. The 17 times improved solubility of CAPE-NIC 
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cocrystal, made it a lead entity to screen for its pharmacokinetic profile upon oral administration. 
Therefore emphasis was given on analyzing the absorption characteristics of the cocrystal in 
terms of plasma Cmax and AUC values. No attempts were made to study detailed tissue 
distribution or in vivo side effects of the cocrystal samples. NIC is listed in the FDA’s GRAS list 
and it is widely used and accepted as a food ingredient in many countries.
40
 Also, its LD50 in rat 
is more than 4 gm per Kg per day.
41
 The amount of NIC used in the current study is much lower 
than its LD50, thus suggesting its safety for oral administration to rat. The plasma concentration-
time curves for CAPE in its pure form and CAPE from CAPE-NIC cocrystal are shown in Figure 
8. The pharmacokinetic parameters for both are displayed in Table 5. Upon oral administration, 
CAPE showed Cmax value of 35.2 ± 5.74 ng/mL at the end of 15 min (Tmax) while CAPE-NIC 
cocrystal displayed Cmax value of 75.1 ± 8.62 ng/mL at early 10 min (Tmax). This suggests 
improved rate of absorption with administration of CAPE-NIC cocrystal. From the Figure 8 it is 
also evident that for every time point, CAPE concentrations in plasma of rats administered with 
CAPE-NIC cocrystal were remarkably higher than those administered with pure CAPE. After 
360 min, the observed drug plasma concentrations with CAPE and CAPE-NIC cocrystal were 
1.41 ± 0.48 ng/ml and 5.02 ± 2.60 ng/ml respectively. Further the AUC(0-∞) values after oral 
administration of CAPE and CAPE-NIC cocrystal were found to be 2240 ± 136.71 ng.min/ml 
and 6736 ± 376.27 ng.min/ml respectively. Accordingly the CAPE-NIC cocrystal demonstrated 
high FREL of 2.76 (bioavailability relative to that of parent drug). Moreover the elimination of 
drug appears to be slowed in case of CAPE-NIC cocrystal with ET1/2 of 343 hr while that of 315 
hr for CAPE. Clearly the results attested significant enhancement in systemic absorption of drug 
from CAPE-NIC cocrystal. Modulation of solubility of CAPE by cocrystallization with NIC 
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seems to the most contributing factor in improving the pharmacokinetic profile of same. The 
NIC might have contributed to reduce first pass effect of liver enzymes on CAPE.
11 
Table 5.In vivo pharmacokinetic parameters 
Parameter CAPE CAPE-NIC 
Tmax (min) 15 10 
Cmax 35.2 ± 5.74 75.1 ± 8.62 
AUC0-t 1800 ± 148.26 4253 ± 266.38 
AUC(0-∞) (ng*min/mL) 2440 ± 136.71 6736 ± 376.27 
FREL 1.00 2.76 
A t1/2 (h) 8 1 
D t1/2 (h) 61 22 
E t1/2 (h) 315 343 
 
 
Figure 8. Pharmacokinetic profiles for CAPE and CAPE-NIC. (mean plasma concentration ± SD 
versus time). 
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4. Conclusion 
The study confirms successful formation of novel crystalline phases for CAPE in the form 
CAPE-CAF, CAPE-INIC and CAPE-NIC cocrystals using microwave assisted cocrystallization 
technique. PXRD and DSC confirm synthesis and phase purity of CAPE-CAF, CAPE-INIC and 
CAPE-NIC cocrystals. Raman spectra of cocrystals complemented these results in conferring the 
formation of new crystalline phases of CAPE. Interestingly, the architecture of CAPE-NIC 
cocrystal as revealed by X-ray crystallography demonstrate stabilization of crystal structure by 
an uncommon 1,2-benzenediol-amide heterosynthon. Cocrystallization of CAPE with NIC 
evidently improved its aqueous solubility & pharmacokinetic profile thereby demonstrating 2.76 
folds escalation in bioavailability.   
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SI1. Coformers screened for cocrystallization with CAPE (1:1). 
 
 
 
 
 
No. Coformer Melting 
point 
(°C) 
Solvent 
(60% w/v) 
Observations Inference 
1 Caffeine 
(CAF) 
235-238 Ethanol  i) DSC 
thermogram 
showed melting 
endotherm at 
113.48°C.  
ii) PXRD 
showed distinct 
peak at 2θ value 
3.5. 
Formation of 
CAPE:CAF cocrystal 
was evident  
(however diffraction 
quality single crystal 
was not produced) 
2 Nicotinamide 
(NIC) 
130-131 Ethanol  i) DSC 
thermogram 
showed melting 
endotherm at 
106.67°C.  
ii) PXRD 
showed distinct 
peak at 2θ value 
4.6. 
Formation of 
CAPE:NIC cocrystal 
was evident  
Also diffraction quality 
single crystal was 
produced. 
3. Isonicotinamide 
(INIC) 
155-157 Ethanol  i) DSC 
thermogram 
showed 
melting 
endotherm at 
107.98 °C.  
ii) PXRD 
showed 
distinct peak 
at 2θ value 
4.6. 
Formation of 
CAPE:CAF cocrystal 
was evident. 
(however diffraction 
quality single crystal 
was not produced) 
4. Gallic acid 
 
257-258 Ethanol  DSC 
thermogram 
showed 
endotherm 
peaks at 113.8, 
117.14 and 
275.6 °C.    
No cocrystal was 
produced. 
 
 
No. Coformer Melting 
point 
(°C) 
Solvent 
(60% w/v) 
Observations Inference 
   Methanol  DSC 
thermogram 
showed sharp 
endotherm 
peaks at 127.88 
°C and 
degradation 
above 225 °C 
No cocrystal was 
produced. 
Acetone   DSC 
thermogram 
showed sharp 
endotherm peak 
128.23°C 
No cocrystal was 
produced. 
Ethyl 
acetate  
DSC 
thermogram 
showed sharp 
endotherm peak 
128.23°C 
No cocrystal was 
produced. 
5. p-Coumaric 
acid 
210-212 Ethanol  DSC 
thermogram 
showed 
endotherm peak 
at 126.84 °C and 
degradation 
above 190 °C. 
No cocrystal was 
produced. 
p-Coumaric 
acid 
Methanol  DSC 
thermogram 
showed 
endotherm peak 
at 125.45 °C and 
degradation 
above 190 °C. 
No cocrystal was 
produced. 
p-Coumaric 
acid 
Acetone  DSC 
thermogram 
showed 
endotherm peak 
at 126.50 °C and 
degradation 
above 194 °C. 
No cocrystal was 
produced. 
p-Coumaric 
acid 
Ethyl 
acetate  
DSC 
thermogram 
showed 
endotherm peak 
at 125.80 °C and 
degradation 
above 195 °C. 
No cocrystal was 
produced. 
 
 
 
 
 
 
 
No. Coformer Melting 
point 
(°C) 
Solvent 
(60% w/v) 
Observations Inference 
6. Curcumin 
 
182-184 Ethanol DSC 
thermogram 
showed 
endotherm peak 
at 122.47 °C. 
No cocrystal was 
produced. 
Methanol DSC 
thermogram 
showed 
endotherm peak 
at 122.47 °C. 
No cocrystal was 
produced. 
Ethyl 
acetate 
DSC 
thermogram 
showed 
endotherm peak 
at 122.47 °C. 
No cocrystal was 
produced. 
7. Isoniazid 171-172 Ethanol DSC 
thermogram 
showed 
endotherm peak 
at 101.47 °C. 
No cocrystal was 
produced. 
8. Theophylline 273-274 Ethanol DSC 
thermogram 
showed 
endotherm peak 
at 117.30 °C. 
No cocrystal was 
produced. 
9. Urea 132-134 Ethanol DSC 
thermogram 
showed 
endotherm peak 
at 99.95 and 
133.14 °C. 
No cocrystal was 
produced. 
10. Ibuprofen 75-76 Ethanol DSC 
thermogram 
showed 
endotherm peak 
at 74 and 121.69 
°C. 
No cocrystal was 
produced. 
 
 
SI2.  Details of HPLC method for CAPE analysis 
Waters e-2695 HPLC system integrated with a PDA 2998 detector, Empower 3 software and 
Waters symmetry C18 column (4.6 × 250 mm, 5 µm) maintained at 25 + 0.5 °C was used. 
Elution was carried out using mobile phase methanol: acetonitrile (50: 50 v/v) in an isocratic 
method at a flow rate of 1 mL/min.
1
 CAPE detection was done at 246 nm. Each experiment 
was performed in triplicates.  
SI3. Details of in vivo pharmacokinetic study  
The experiment protocol (CPCSEA/40/12), was approved by Institutional Animal Ethical 
Committee (IAEC) constituted as per guidelines of the Committee for Purpose of Control and 
Supervision of Experiments on Animals Government of India. The animals were housed 
under standard conditions of temperature (24 ± 1 °C), relative humidity (55 ± 10%) and 12 
hrs light/dark cycles during said period. Animals had free access to standard pellet diet, 
filtered water ad libitum and were acclimatized for a period of one week prior to study. The 
animals were starved overnight prior to the study. Vegetable oil was used as gavage vehicle 
as all the crystal forms were found insoluble in it. The blood samples were mixed thoroughly 
with di-sodium EDTA to prevent clotting and centrifuged at 10,000 rpm for 15 min at 4 °C. 
The separated plasma was transferred to pre-labeled tubes containing sodium fluoride 
(0.25%) and acetate buffer (0.1M) to ensure the integrity of CAPE during storage at -80 °C 
till analysis.
2,3 
Quantification of CAPE in Rat plasma 
Standard solutions of CAPE and internal standard (IS), Taxifolin were prepared by dissolving 
each 10 mg in methanol 10 ml. The working standard solutions were prepared by diluting the 
stock solutions with mobile phase and spiked into the blank plasma to produce plasma 
 
 
standards. The plasma samples were analysed for CAPE content by HPLC as per reported 
method
 
with minor modifications. Briefly, 200 µl of each plasma sample was mixed with 100 
µl of IS (100 µg/ml) and extracted with 600 µl of ethyl acetate by vortexing for 15 min. The 
collected supernatant phase from both extractions was dried under nitrogen flow at room 
temperature. The dried residues each were reconstituted with 200 µl acetonitrile, filtered 
through 0.45μm nylon syringe and subjected to HPLC analysis for determination of CAPE 
content using Waters e-2695 system integrated with a PDA 2998 detector, Empower 3 
software and Waters symmetry C18 column (4.6 × 250 mm, 5 µm) maintained at 25 ± 0.5 °C 
throughout study. Elution was carried out with flow rate of 0.5 mL/min at ambient 
temperature. The solvents comprised acetonitrile (solvent A) and water (solvent B) both with 
0.5% formic acid mixed using linear gradient system: initial 85% B, 25% B in 3 min, 10% B 
in 10 min, 0 % B in 15 min followed by isocratic 85% B held constant till 45 min. Detection 
was performed between 200 to 400 nm and chromatograms were extracted at 328 nm. The 
concentration range of the standard curve was 2 to 20 ng/mL of CAPE.  
Data analysis 
Pharmacokinetic parameters were calculated for the set of data by two compartment analysis 
using WinNonLin version 4.0 (Pharsight, Mountain View, CA,). 
 
 
 
 
 
 
 
 
 
SI4. Differential Scanning Calorimetry (DCS), Heat-Cool-Heat study for CAPE-NIC,            
  CAPE-INIC and CAPE-CAF co-crystals. 
 Figure SI4.A. DSC thermogram of CAPE-NIC co-crystal, Heat-Cool-Heat cycle. 
 
 
Figure SI4.B. DSC thermogram of CAPE-INIC co-crystal, Heat-Cool-Heat cycle. 
 
 
 
 
 
 
 
Figure SI4.C. DSC thermogram of CAPE-CAF co-crystal, Heat-Cool-Heat cycle. 
 
SI5. Refcodes with 1,2-benzenediol and amide functional groups in the same crystal         
structure. 
EVIJUO FIXROV GAZWUB HEDRAL HEDREP 
HEDRIT HEDROZ HUMJII MUPMOA MUPNAN 
MUPNUH MUPPAP NAXHOL PEFGEO PEFGEO01 
PEFGEO02 PEFGEO03 PEFGIS REBXIH VEQTIW 
ZEBXEL ZEBXIP ZEBXOV ZEBXUB ZIKNOY 
ZIKPAM ZIKPUG    
The refcodes marked in RED represent crystal structures with benzene diol and amide 
heterosynthon 
The refcodes marked in BLUE represent crystal structures with competing homosynthons 
such as amide-amide, OH-OH etc 
The refcodes marked in BLACK represent crystal structures with other heterosynthons such 
as acid-amide, amide-pyridine etc. 
 
 
 
 
 
 
 
 
SI6. HPLC Chromatograms of CAPE and its cocrystals. 
 
Figure SI6.A. Representative HPLC chromatogram of CAPE. 
 
Figure SI6.B. Chromatogram for CAPE-CAF. The chromatogram depicts elution at 3.123 
min for CAF and 3.80 min for CAPE. 
 
 
 
Figure SI6.C. Chromatogram for CAPE-INIC. The chromatogram depicts elution at 2.915 
min for INIC and 3.70 min for CAPE. 
 
Figure SI6.D.Chromatogram for CAPE-NIC. The chromatogram depicts elution at 3.006 min 
for NIC and3.684 min for CAPE. 
 
 
 
SI7. BDFH morphology crystals (calculated) 
 
Figure SI7.A.  BFDH model of CAPE-NIC showing the projected diol groups long the major 
(100) face. (Projected parallel to the (100) face) 
 
Figure SI7.B. BFDH model of CAPE-NIC showing the projected diol groups long the major 
(100) face. (Projected perpendicular to the (100) face) 
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